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Abstract
Meta-analyses have been extensively used to evaluate the eﬃcacy of neurofeedback (NFB)
treatment for Attention Deﬁcit/Hyperactivity Disorder (ADHD) in children and adolescents.
However, each meta-analysis published in the past decade has contradicted the methods and
results from the previous one, thus making it diﬃcult to determine a consensus of opinion on
the eﬀectiveness of NFB. This works brings continuity to the ﬁeld by extending and discussing
the last and much controversial meta-analysis by Cortese et al. [2016].
The extension comprises an update of that work including the latest control trials, which
have since been published and, most importantly, oﬀers a novel methodology. Speciﬁcally, NFB
literature is characterized by a high technical and methodological heterogeneity, which partly
explains the current lack of consensus on the eﬃcacy of NFB. This work takes advantage of
this by performing a Systematic Analysis of Biases (SAOB) in studies included in the previous
meta-analysis.
Our extended meta-analysis (k = 16 studies) conﬁrmed the previously obtained results of
eﬀect sizes in favor of NFB eﬃcacy as being signiﬁcant when clinical scales of ADHD are rated
by parents (non-blind, p-value = 0.0014), but not when they are rated by teachers (probably
blind, p-value = 0.27). The eﬀect size is signiﬁcant according to both raters for the subset
of studies meeting the deﬁnition of "standard NFB protocols" (parents' p-value = 0.0054;
teachers' p-value = 0.043, k = 4). Following this, the SAOB performed on k = 33 trials
identiﬁed three main factors that have an impact on NFB eﬃcacy: ﬁrst, a more intensive
treatment, but not treatment duration, is associated with higher eﬃcacy; second, teachers
report a lower improvement compared to parents; third, using high-quality EEG equipment
improves the eﬀectiveness of the NFB treatment.
The identiﬁcation of biases relating to an appropriate technical implementation of NFB
certainly supports the eﬃcacy of NFB as an intervention. The data presented also suggest
that the probably blind assessment of teachers may not be considered a good proxy for blind
assessments, therefore stressing the need for studies with placebo-controlled intervention as
well as carefully reported neuromarker changes in relation to clinical response.
Keywords: ADHD, neurofeedback, meta-analysis, analysis of bias
1 Introduction
Attention Deﬁcit/Hyperactivity Disorder (ADHD) is a common childhood psychiatric disorder char-
acterized by impaired attention and/or hyperactivity/impulsivity. Symptoms may persist in adult-
hood with clinical signiﬁcance, which makes ADHD a life-long problem for many patients [Faraone
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et al., 2006]. The prevalence of ADHD is around 5% in school-aged children, thus aﬀecting an
estimated 2.5 million children in Europe [The American Psychiatric Association, 2013]. ADHD neg-
atively impacts children's well-being, with many suﬀering from low self-esteem [Shaw-Zirt et al.,
2005] and underachievement in school [Barry et al., 2002]. Parents are equally aﬀected, since the
child's behavior is frequently attributed to bad parenting [Harpin, 2005]. From a societal point of
view, ADHD also has a high ﬁnancial impact: a 2013 survey in Europe estimated costs related to
ADHD between 9, 860 and 14, 483 Euros per patient/year [Le et al., 2014].
The diagnosis of ADHD primarily relies on questionnaire-based clinical evaluation [The American
Psychiatric Association, 2013], which can be supported by objective assessment metrics of execu-
tive function such as the Test of Variables of Attention (TOVA) [Forbes, 1998], the Continuous
Performance Test (CPT) [Barkley, 1991], and the Sustained Attention to Response Task (SART)
[Robertson et al., 1997]. Objective markers of brain function using electroencephalogram (EEG),
functional Magnetic Resonance Imaging (fMRI), or Positron Emission Tomography (PET) are not
considered to be useful for improving diagnosis at the individual level, but can help in diﬀerentiating
groups of patients [Johnstone et al., 2005]. In particular, diﬀerent phenotypes of ADHD patients
present with an increase in the EEG theta wave power (4-8Hz) and/or a decrease of EEG beta wave
power (12-32Hz) in frontal areas, or a decrease in the EEG Sensorimotor Rhythm (SMR) power
(13-15Hz) in the central area [Monastra, 2005; Matou²ek et al., 1984; Janzen et al., 1995; Loo
et al., 2017]. A device using EEG to help clinicians more accurately diagnosis ADHD was cleared
by the Food and Drug Administration (FDA) [Neba Health, 2015].
Psychostimulants are the most common treatment currently in use, and have proven to be
eﬃcacious [Taylor, 2014; Storebo et al., 2015]. However, their long-term eﬀectiveness and side
eﬀects are still debated and form an active area of research [DuPaul, 1998; Swanson et al., 2001;
Jensen, 1999; Su et al., 2016; Becker et al., 2016]. Moreover, ADHD children under medication
commonly suﬀer from mild side eﬀects such as loss of appetite and sleep disturbance, although serious
adverse events are rare [Storebo et al., 2015; Cooper et al., 2011]. These drawbacks make some
parents and clinicians reluctant to opt for such treatment, instead turning to non-pharmaceutical
alternatives such as dietary changes [Bélanger et al., 2009] and behavioral therapy, which have been
proven to be less eﬃcacious [Sonuga-Barke et al., 2013].
Neurofeedback (NFB) is another non-pharmaceutical and non-invasive approach aiming at the
reduction of ADHD symptoms [Arns et al., 2015; Steﬀert and Steﬀert, 2010; Marzbani et al.,
2016]. Shortly after the discovery of the brain's electric activity by Berger [1929], Durup and
Fessard [1935] demonstrated it could be voluntarily modulated, leading to a series of ﬁndings on
the self-regulation of brain activity. The ﬁrst indication of the therapeutic potential of brain activity
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operant-conditioning came forty years later when Sterman et al. [1974] found that training the SMR
activity reduces the incidence of epileptic crisis in kerosene-exposed cats. The technique, then known
as NFB, rapidly became the subject of investigation in various ﬁelds of neuropsychiatry including,
most notably, ADHD [Lubar and Shouse, 1976; Rossiter and La Vaque, 1995; Linden et al., 1996;
Maurizio et al., 2014].
NFB is a self-paced brain neuromodulation technique that represents brain activity in real-time
using auditory or visual modulations, on which learning paradigms, such as operant conditioning
[Reynolds, 1975] or voluntary control, can be applied. To deliver this intervention, neurophysiological
time series are analyzed online in order to drive feedback applications such as serious games [Wang
et al., 2010]. The signal of interest should represent the activity of a population of neurons involved
in attentional networks, which is translated into visual or auditory cues. The sensory feedback
constitutes the rewards mechanism, promoting learning using, for instance, operant conditioning
protocols [Sherlin et al., 2011]. Operant conditioning enables neural plasticity, thus supporting
the child in the task repetition [Skinner, 1984], which is believed to result in long-lasting neuronal
reorganization [Van Doren et al., 2017].
Several NFB protocols have been proposed and investigated for decreasing the symptoms of
ADHD:
• protocols based on neural oscillations, using frequency-band power training: enhancing SMR
[Beauregard and Levesque, 2006], reducing theta [Marzbani et al., 2016] or enhancing beta
[Kropotov et al., 2005], or a composite protocol such as enhancing beta while suppressing
theta, also known as the Theta Beta Ratio (TBR) protocol [Lubar and Shouse, 1976; Arns
et al., 2013];
• protocols based on Slow Cortical Potentials (SCPs) training consisting of the regulation of
cortical excitation thresholds by focusing on activity generated by external cues [Heinrich et al.,
2004; Banaschewski and Brandeis, 2007];
• protocols to enhance Event-Related Potentials (ERPs): in particular, the amplitude of the
P300 ERP can be considered as a speciﬁc neurophysiological marker of selective attention
[Fouillen et al., 2017].
Moreover, NFB protocols can be personalized: some studies did not use the usual deﬁnitions of
EEG band ranges but determined them thanks to the individual Alpha Peak Frequency (iAPF)
[Klimesch, 1999], giving individualized NFB protocols [Liu et al., 2016; Escolano et al., 2014;
Bazanova et al., 2018].
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NFB eﬃcacy on the core symptoms of ADHD (inattention, hyperactivity, and impulsivity) has
been the subject of several meta-analytic studies [Loo and Barkley, 2005; Lofthouse et al., 2012;
Arns et al., 2009; Micoulaud-Franchi et al., 2014; Sonuga-Barke et al., 2013]. To date, studies have
not reached a consensus on the eﬃcacy of NFB; while Arns et al. [2009] and Micoulaud-Franchi
et al. [2014] claim results in favor of its eﬃcacy, especially on the inattention component highlighted
by Micoulaud-Franchi et al., other authors, such as Loo and Barkley [2005]; Lofthouse et al. [2012],
and Sonuga-Barke et al. [2013] express their reservations, asking for further evidence from blind
assessment.
The most recent meta-analysis addressing the eﬃcacy of NFB was published by Cortese et al.
[2016], including a total of 13 Randomized Controlled Trials (RCTs). The results of this analysis are
mixed: when based on parent assessments, which are not blind to treatment, they are signiﬁcantly in
favor of NFB, whereas when the evolution of symptoms is rated by teachers (considered as probably
blind), the results are no longer signiﬁcant. The authors concluded that further evidence from blind
assessments is needed in order to support NFB as a treatment for ADHD symptoms. However, some
of the choices made in this meta-analysis, which may have had an impact on the results, have since
been debated by the community. Speciﬁcally, Micoulaud-Franchi et al. [2016] criticized the use of
an uncommon behavioral scale provided by Steiner et al. [2014] for the teachers' assessments and
the inclusion of a pilot study carried out by Arnold et al. [2014].
As a result of these criticisms and the concurrent publication of new RCTs meeting Cortese
et al.'s inclusion criteria, we decided to update this meta-analysis and take the opportunity to inves-
tigate the impact of its controversial choices. While performing our investigation, we observed two
shortcomings: the assumption that the diﬀerence between teacher and parent assessments can solely
be explained by the placebo eﬀect, and pooling together heterogeneous studies in terms of method-
ology and technical implementation. An interesting approach, albeit not commonly performed, to
assess the NFB eﬃcacy would be to analyze the speciﬁcity of the EEG changes with respect to
trained neuromarkers [Maurizio et al., 2014]. In our case, based on the data at our disposal, we
used the technical and methodological heterogeneity of the NFB trials to our advantage rather than
disadvantage by extending the previous work with a novel method, the Systematic Analysis of Biases
(SAOB). Indeed, the NFB domain is characterized by clinical literature that is extremely heteroge-
neous: studies diﬀer methodologically (for instance, random assignment and presence of a blind
assessment), in the NFB implementation (for instance, number of sessions, session and treatment
length, and type of protocol) as well as on the acquisition and processing of the EEG signal. De-
scription and analysis of diﬀerent types of NFB implementation was subject to several studies [Arns
et al., 2014; Enriquez-Geppert et al., 2017; Vernon et al., 2004; Jeunet et al., 2018]. However to
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the best of our knowledge, none of these studies has used statistical tools to quantify their inﬂuence
on clinical endpoints.
Since methodological and technical implementations of studies are highly likely to inﬂuence their
outcomes [Congedo et al., 2004], we suggest identifying which of the factors independently inﬂuence
the clinical eﬃcacy with the use of appropriate statistical tools. In addition, we have made available
all the raw RCT data we have used and a complete Python library for performing meta-analysis
[Bussalb, 2019a]. Through doing so, we hope to foster the replication of our and previous studies
and to facilitate similar future projects.
2 Materials and Methods
2.1 Inclusion criteria
Search terms were directly taken from Cortese et al. [2016] with the exception of the need for
a control arm, which is detailed in Supplemental Materials [Bussalb, 2019b]. The requirements
included:
• studies have to assess NFB eﬃcacy;
• subjects must have received a diagnosis of ADHD based on DSM-IV [The American Psychiatric
Association, 2000], DSM-5 [The American Psychiatric Association, 2013], ICD-10 [World
Health Organization, 1993] criteria, or by a qualiﬁed psychiatrist;
• studies have to be written in English, German, Spanish, or French;
• studies have to include at least eight subjects in each group;
• patients must be younger than 25 years old;
• the publication has to disclose suﬃcient details about the data to compute required metrics
for the ensuing analysis.
The studies satisfying all these criteria were included in the SAOB. In order to replicate and update
Cortese et al.'s meta-analysis, we applied the original inclusion criteria of their meta-analysis to our
search (the main diﬀerence being the presence of a control group).
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2.2 Outcome deﬁnition
In the included studies, the severity of ADHD symptoms have been assessed by parents and, whenever
available, by teachers. Cortese et al. [2016] and Micoulaud-Franchi et al. [2014] deﬁned parents
as Most Proximal (MPROX) raters who were not blind to the treatment, as opposed to teachers,
who were considered as Probably Blind (PBLIND) raters. This distinction is intended to assess the
amplitude of the placebo eﬀect, where it is hypothesized that teachers, who are presumed to be
more blind to the intervention, are less inﬂuenced in their assessment. Eﬃcacy of NFB was measured
using clinical scales, such as the ADHD-RS [Pappas, 2006], on the following outcomes: inattention,
hyperactivity/impulsivity, and total scores. The factor analysis was performed using the total score.
2.3 Meta-analysis
The goal of a meta-analysis is to aggregate results from diﬀerent clinical investigations and oﬀer a
consolidated body of evidence. To achieve this, it is necessary to assume some level of homogeneity
in the design of the studies: inclusion criteria, and the presence and type of control (active, semi-
active, or non-active). Because studies occasionally use slight variations of a clinical scale and
because of the clinical heterogeneity of patients and control, the scores are standardized before
being pooled into a Summary Eﬀect (SE). The between-Eﬀect Size (ES) is one such standardized
metric, which we have implemented in this paper (see Supplemental Materials [Bussalb, 2019b]).
The meta-analysis was performed with a Python package developed for this work. The package
oﬀers a transparent approach for the choice of parameters in an eﬀort to ease replicability. We
have benchmarked it against RevMan version 5.1 [Cochrane Collaboration, 2011, UK, London] by
replicating Cortese et al. [2016]'s work. The code is made fully available on a GitHub repository
[Bussalb, 2019a], together with all the RCTs raw data we have used in the present study.
Before updating the Cortese et al. [2016] work with recently published studies [Strehl et al.,
2017; Baumeister et al., 2016], we decided to run a sensitivity analysis investigating the choices that
later proved controversial [Micoulaud-Franchi et al., 2016]. The investigated changes included:
• the between-ES of Arnold et al.'s study was computed from the post-test clinical values taken
after the completion of the 40 sessions, in contrast to Cortese et al. [2016]'s report which
used the results after only 12 sessions because the endpoint values were not available at the
time of his study;
• the between-ES computed from the teachers' assessment reported by Steiner et al. [2014] relied
on the BOSS Classroom Observation [Shapiro, 2010]. This is an atypical scale to quantify
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ADHD symptoms since the Conners Rating Scale Revised [Conners et al., 1998; Christiansen
et al., 2014; Bluschke et al., 2016], a well-deﬁned [Collett et al., 2003; Epstein and Weiss,
2012] and broadly used metric, was available in this study. Thus, we decided to compute
the between-ES based on the Conners-3 already used in this study to compute the parents'
between-ES.
As initially suggested by Cortese et al., the analysis was run on two subgroups of studies with
the two choices described above: one gathering studies following the standard protocol deﬁned by
Arns et al. [2014] and a second including only participants not taking medications during the clinical
trial.
2.4 Identify factors inﬂuencing the neurofeedback
While revisiting the existing meta-analyses, it became apparent that the studies pooled together
were highly heterogeneous in terms of methodological and practical implementation. For instance,
all NFB interventions were pooled together regardless the quality of acquisition, the quality of EEG
data, and the trained neuromarker. Equally, the methodological implementations varied signiﬁcantly,
requiring the 'subgroup' analysis (for instance, gathering studies following standard protocols) that
are somewhat arbitrary. To circumvent these limitations, we implemented a novel approach: the
SAOB. With this method, the within-ES of each intervention was considered as a dependent variable
to be explained by methodological and technical factors. Such analysis aims at identifying known
methodological biases (e.g. blind assessments negatively associated with within-ES) and possible
technical factors (e.g. a good control on real time data quality positively inﬂuences the treatment
outcome).
2.4.1 Identify and pre-process factors
We classiﬁed the factors inﬂuencing the eﬃcacy of NFB into ﬁve categories: methodological, tech-
nical, demographics, and quality of the signal and acquisition. Factors were chosen based on that
reported in the literature as presumed to inﬂuence ES, and categorized as follows:
• the methodological biases: the presence of a control group, the blindness of assessors, the
randomization of subjects in controlled trials, and the approval of the study by an Institutional
Review Board (IRB);
• the population: intake of psychostimulants during NFB treatment, the age range of children
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included, the severity of ADHD symptoms at baseline1, and the degree of engagement with
NFB intervention;
• the NFB implementation: the protocol used (SCP, SMR, theta up, beta up in central or frontal
areas, theta down), the presence of a transfer phase during NFB training, the possibility to
train at home or at school with a transfer card, the type of thresholding for discrete reward,
the number of NFB sessions, the length and frequency of the sessions, the length of the
treatment, the individualization of the frequency bands based on the iAPF, and coupling NFB
with Electromyogram (EMG)-Biofeedback;
• the acquisition quality : the presence of one or more active electrodes and the EEG data quality.
The latter was coded as an indicator between 1 and 3, using the following criteria:
the type of electrodes used : Silver Chloride (AgCl)/Gel or Gold (Au)/Gel;
the use of impedance mode: a quality check of electrode contacts ensuring an inter-
electrode impedance smaller than 40kΩ;
the level of hardware certiﬁcate: compliance with ISO-60601-2-26 [International Elec-
trotechnical Commission, 2012].
A quality score equal to 3 was assigned if all the above criteria were satisﬁed. If at least one
was satisﬁed the quality score was set to 2, otherwise the score was set to 1.
• the signal quality : online rejection (epoch rejected, feedback not computed) or correction
(feedback computed on the denoised epoch) of Electro-Oculogram (EOG) artifacts, and online
rejection of generic artifacts using an amplitude-based detection.
To prevent any bias in the analysis, the names of the factors were hidden during the entire
analysis so that the data scientists (AB, QB, DO, and LM) were fully blind to them. The names
were revealed only when the data analysis and results were accepted as valid: this included choice
of variable normalization and validation of model hypothesis, as detailed below.
The pre-processing of factors for the analysis included the following steps: factors for which there
were too many missing observations arbitrarily set to more than 20% of the total observations, were
removed from the analysis. Furthermore, if a factor had more than 80% similar observations it was
also removed. A study did not systematically correspond to an observation: when several clinical
1Baseline severity is given by the pre-treatment score. But, to have comparable severity scores between the
diﬀerent clinical scales, pre-treatment score is normalized, i.e. divided by the maximal score which can be obtained
on the clinical scale
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scales and/or raters were available in a study, each couple clinical scale - rater was considered as
an observation. Categorical variables were coded as dummies, i.e., the presence of the factor was
represented with 1 and its absence with 0. All variables were standardized by subtracting the mean
and then dividing by the standard deviation (not applied before the decision tree described below).
2.4.2 Explaining within eﬀect sizes with factors
To compute the within-ES, the means of total ADHD scores given by parents and teachers were
used. Moreover, in case studies providing results for more than one behavioral scale the within-ES
scores were computed for each one as:
ES =
Mpost,T −Mpre,T√
σ2
pre,T
+σ2
post,T
2
,
where Mt,T is the mean of clinical scale, for treatment T, taken at time t (pre-test or post-test) and
σt,T represents its standard deviation. With this deﬁnition, we focus on the eﬀect of the treatment
within a group [Cohen, 1988] as commonly reported in the literature [Arns et al., 2009; Maurizio
et al., 2014; Strehl et al., 2017]. This within-ES enables us to quantify the eﬃcacy of NFB inside
the treatment group. Finally, to avoid to break analysis methods assumptions, an outlier rejection
was applied deﬁning thresholds of acceptance as [µ− 3σ, µ+ 3σ], with µ and σ being respectively
the mean and the standard deviation of all within-ES computed [Shewhart, 1931].
The within-ES was then considered as a dependent variable to be explained by the factors (the
independent variables). The following three methods, implemented with the Scikit-Learn Python
[Pedregosa et al., 2011, version 0.18.1] and the Statsmodels Python [Seabold and Perktold, 2010,
version 0.8.0] libraries, were used to perform the regression:
• weighted multiple linear regression with Weighted Least Squares (WLS) [Montgomery et al.,
2012];
• sparsity-regularized linear regression with Least Absolute Shrinkage and Selection Operator
(LASSO) [Tibshirani, 1996];
• decision tree regression [Quinlan, 1986].
The aim of the linear regression is to estimate the regression coeﬃcients linking the factors to
the within-ES. A signiﬁcant coeﬃcient (here and hereafter meaning signiﬁcantly diﬀerent from zero)
indicates that the associated factor has an inﬂuence on NFB eﬃcacy and its sign the direction of the
eﬀect. The WLS diﬀers from a traditional linear regression estimated with Ordinary Least Squares
(OLS) in that a weight is assigned to each observation in order to account for the multiplicity of
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reported clinical endpoints in some studies. In addition, the weight was also set as a function of
the sample size to account for variations in sample sizes. Speciﬁcally, the weight of each study was
taken as the ratio between the experimental group's sample size and the number of behavioral scales
available. We also ran the analysis using the OLS method to assess the impact of the weights on
the results.
The second linear method applied was the LASSO, which naturally incorporates variable selection
into the linear model thanks to `1-norm applied on the coeﬃcients. A coeﬃcient not set to zero
means that the associated factor has an inﬂuence on NFB eﬃcacy and its sign indicates the direction
of the eﬀect.
The last method used to determine factors inﬂuencing NFB was the decision tree [Quinlan, 1986],
a hierarchical and non-linear method. This breaks down a dataset into smaller and smaller subsets
using, at each iteration, a variable and a threshold chosen to optimize a simple Mean Square Error
(MSE) criterion [James et al., 2013]. A tree is composed of several nodes and leafs, the importance
of which decreases from the top node, called the root node, downward.
Given that these methods are intrinsically diﬀerent we compared their results. For instance,
the decision tree captures variable interactions and can relate factors to within-ES in a non-linear
fashion. On the other hand, the LASSO oﬀers an elegant mathematical framework for variable
selection. Further details are provided in the Supplemental Material [Bussalb, 2019b].
3 Results
3.1 Selected studies
Search terms entered in Pubmed returned 155 results during the last check on February 12, 2018, in-
cluding 22 articles used in previous meta-analyses on NFB. Following the selection process illustrated
in Figure 1, 33 studies were included in the SAOB and 16 in the meta-analysis, as summarized in
Table 1. The 33 studies selected for the SAOB followed Cortese et al.'s criteria, with the exception
of the requirement for a control group. Indeed, since within-ES were considered in this analysis, a
control group was not required.
3.2 Meta-analysis
The replication of Cortese et al.'s results obtained are presented in Table 2:
• when computing the between-ES for Arnold et al. [2014] with the values after 40 sessions of
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NFB, smaller between-ES were found as compared to those found by Cortese et al. [2016],
which was unexpected since the clinical eﬃcacy is supposed to increase with the number
of NFB sessions. These lower between-ES impacted the SE: they were slightly lower when
computed with this choice although they nonetheless remained signiﬁcant (see the three ﬁrst
lines of Table 2);
• when relying on the teachers' ratings from the Conners-3 to compute the between-ES of
Steiner et al. [2014], higher SEs were found in attention but not for total and hyperactivity
score. However, this diﬀerent choice of scale did not aﬀect the statistical signiﬁcance of the
SEs (see the three last lines of Table 2).
The meta-analysis was then extended by adding three new articles [Strehl et al., 2017; Baumeister
et al., 2016; Bazanova et al., 2018]. Bazanova et al. [2018] gave parents' assessments for all
outcomes, Baumeister et al. [2016] provided results solely for parents' total outcome, whereas Strehl
et al. [2017] gave both teachers' and parents' assessments for all outcomes. To be consistent with the
SAOB, only the standard NFB group of Bazanova et al. [2018] was included in this update. Despite
favorable results for NFB, particularly on parents' assessments, adding these three new studies did
not change either the magnitude or the signiﬁcance of the SE, for any outcome regardless of the
raters, as illustrated in Figure 2.
Regarding the "standard protocol" subgroup, Cortese et al. [2016] found all the outcomes sig-
niﬁcant except for the hyperactivity symptoms rated by teachers, which showed only a statistical
trend (p-value = 0.11). Similar results were obtained when adding the most recent studies meeting
this deﬁnition [Strehl et al., 2017; Baumeister et al., 2016] (p-value = 0.11). The SE for the total
outcome assessed by teachers remained signiﬁcant with the addition of the new RCT (p-value =
0.043), thus giving more strength to this result since it is now based on four studies including 283
patients in total.
As for the no-drug subgroup, SEs were found signiﬁcant for the inattention symptoms assessed
by parents (p-value = 0.017). In addition, the diﬀerences in Arnold et al. [2014] values and the
inclusion of Bazanova et al. [2018] caused a loss of signiﬁcance in hyperactivity outcome for parents
(p-value = 0.062) compared to Cortese et al. [2016] (p-value = 0.016). Only Bazanova et al. [2018]
was included in this subgroup: in the two other studies the subjects were taking psychostimulants
during the trial.
All the clinical scales used to compute the between-ES following our choices are summarized in
the Supplemental Materials.
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3.3 Factors inﬂuencing Neurofeedback
This analysis was performed on 33 trials (corresponding to 67 observations) assessing the eﬃcacy of
NFB, as presented in Table 1. The outlier rejection removed two training groups of Bazanova et al.
[2018] from the analysis because their within-ES were out of the bounds. Among the 28 factors
selected, nine were removed because there were too many missing observations or because they were
too homogeneous: beta up in frontal areas, the use of a transfer card, the type of threshold for
the discrete rewards (incremental or ﬁxed), the EEG quality equal of 3, the presence of a control
group, the individualization of the frequency bands based on the iAPF, coupling NFB with EMG-
Biofeedback, the severity of ADHD symptoms at baseline, and the degree of engagement with NF
intervention.
All results are presented in Table 3. These results, require careful interpretation since each tech-
nique provided slightly diﬀerent results. These diﬀerences may depend on the diﬀerent assumptions
of the model and several other factors. Nonetheless, we are inclined to trust the ﬁndings that are
consistent across methods.
The WLS technique identiﬁed nine signiﬁcant factors for an adjusted R-squared of 0.62 (see
second column of Table 3). When applying the OLS, the same factors were signiﬁcant except the
EEG quality equal of 2 and the presence of more than one active electrode) with a lower adjusted R-
squared (0.35). The LASSO regression selected six signiﬁcant factors (see third column of Table 3).
With these methods, a negative coeﬃcient means that the factor is in favor of the eﬃcacy of NFB.
The decision tree is presented in Figure 3: the best predictor in our case was the PBLIND (see last
column of Table 3). Four other factors also split the subsets; however, increasingly fewer samples
are available the lower we get into the tree, making the interpretation increasingly doubtful.
Several factors were common to the three methods used. These included, in particular: the
assessment by a blind rater, the treatment length, and an EEG quality score equal to 2 (see lines 1,
9, and 19 of Table 3). The methods also agreed on the direction of the eﬀect for these factors: a
shorter treatment and recording of the EEG with a good-quality system appears preferable, whereas
teachers' assessment appears less favorable compared to parents' assessment.
It is more doubtful the inﬂuence of the factors returned by only one or two methods (see lines
2, 3, 7, 8, 11, 16, 17, and 20 of Table 3). In particular:
• both WLS and LASSO found that using more than one active electrode during NFB appears
to lead to an higher eﬃcacy;
• both WLS and the decision tree found that performing a higher number of sessions seems to
be preferable;
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• both LASSO and the decision tree found that a higher number of sessions per week appears
to positively inﬂuence the eﬃcacy of the NFB treatment.
Five factors were returned by only one of the methods: randomizing the groups, the IRB approval,
the session length, the presence of a transfer phase, and the correction or rejection of ocular artifacts.
Eight factors were never selected by the three methods (see lines 4, 5, 6, 12, 13, 14, 15 and 22
of Table 3): the children's minimum and maximum age, being on drugs during NFB treatment, the
protocols SMR, beta up in central areas, theta down, and SCP, and the artifact correction based on
amplitude. Thus, these factors overwhelmingly appear not to have an inﬂuence on NFB eﬃcacy.
In the next section we discuss only the factors that were selected by at least two of the three
methods.
4 Discussion
4.1 Meta-analysis
This replication and update of a meta-analysis did not meet all PRISMA recommendations [Moher
et al., 2009]. In particular, the risk of bias in individual and across studies was not assessed.
In the meta-analysis performed here, we challenged some choices made by Cortese et al., which
proved controversial: the computation of between-ES based on an unusual scale [Steiner et al., 2014]
and the inclusion of a pilot study [Arnold et al., 2014] whose endpoint values were not available at
the time Cortese et al. conducted their meta-analysis. We here review the list of changes, their
justiﬁcation, and their impact on the analysis.
First, relying on the Conners-3 [Conners et al., 2011] instead of the BOSS Classroom Observation
[Shapiro, 2010] for teachers' ratings seems preferable because this scale is more commonly used
[Christiansen et al., 2014; Bluschke et al., 2016] and is a revision of the Conners Rating Scale
Revised [Conners et al., 1998] whose reliability has been studied [Collett et al., 2003]. However,
relying on one or the other scale did not change the signiﬁcance of the between-ES, regardless of
outcome.
Second, to compute the between-ES of Arnold et al. [2014] the clinical scores taken when all
sessions were completed were used instead of looking at interim results as with Cortese et al.. Some
studies suggested that the number of sessions correlates positively with the changes observed in
the EEG [Vernon et al., 2004] so that a lower number of sessions would lead to artiﬁcially smaller
between-ES. Here, the between-ES computed with the values at post test of Arnold et al. [2014]
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were smaller than those obtained after 12 sessions; however, these diﬀerences did not lead to a
change of signiﬁcance of the SE.
To conclude on this meta-analysis, although some points were controversial, the impact on the
meta-analysis was minimal and did not change the statistical signiﬁcance of any outcome. The
addition of the three new studies [Strehl et al., 2017; Baumeister et al., 2016; Bazanova et al.,
2018] further conﬁrmed the original results. Indeed, the signiﬁcance did not change for any outcome:
the SE remained signiﬁcant for MPROX raters and non-signiﬁcant for PBLIND. Adding three more
studies increased the signiﬁcance of the sensitivity analysis run by Cortese et al., most notably the SE
of studies corresponding to NFB "standard protocols" [Arns et al., 2014]. While Cortese et al. found
that this subset tends to perform better, particularly on the PBLIND outcome, adding two studies
conﬁrmed this result on the total clinical score (p-value < 0.05). Despite the obvious heterogeneity
of the studies included in this subset (particularly in terms of protocol used), these results suggest a
positive relation between the features of this standard design and NFB performance. This result is
a breakthrough in the demonstration of standard NFB protocol eﬃcacy for the treatment of ADHD.
Nonetheless, the studies included in this subset are still highly heterogeneous (particularly in terms
of protocol used), a factor which should be accounted for.
4.2 Factors inﬂuencing neurofeedback
Description and analysis of diﬀerent types of NFB implementation were subject to several studies
[Arns et al., 2014; Enriquez-Geppert et al., 2017; Vernon et al., 2004; Jeunet et al., 2018; Arns
et al., 2009; Cortese et al., 2016]. However, to the best of our knowledge, none of these studies has
implemented a systematic multivariate approach to associate factors to clinical endpoints therefore
exposing their univariate analysis to a greater extend to the presence of a confounding factor.
Two observations were detected as outliers and so removed from the dataset before perform-
ing the SAOB: Bazanova et al.'s individualized NFB and individualized NFB coupled with EMG-
Biofeedback groups. Indeed, these two groups presented very large within-ES (-3.41 and -3.95),
even bigger than those reported in the literature on medication treating ADHD [Luan et al., 2017].
These large values broke our working hypothesis, so in order to be able to conclude on the results
obtained by the SAOB, an outlier rejection was implemented.
As expected, the number of sessions was found to be signiﬁcant, even if it was by only two
methods, which was in compliance with existing literature. For instance, using several univariate
regressions without correction for multiple testing Arns et al. [2009], Arns et al. [2014] stated
that performing less than 20 NFB sessions leads to smaller eﬀects. Similarly, Vernon et al. [2004]
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observed that positive changes in the EEG and behavioral performance occurred after a minimum
of 20 sessions. However, Enriquez-Geppert et al. [2017] insisted that the number of sessions should
be carefully chosen in order to avoid "overtraining". The fact that the number of sessions was not
identiﬁed by the LASSO as a positively contributing factor might be explained by the presence of
only two data points with 20 sessions or less. Conceivably, the temporal threshold of eﬃcacy was
passed for all included studies, making the identiﬁcation of this factor by the three methods unlikely
on this dataset. However, the two methods that identiﬁed this factor both agreed that as expected,
the more sessions performed, the more eﬃcient the NFB tends to be.
Interestingly, [Minder et al., 2018] suggests that the subject location of the NFB training may
also be an important contributory factor to clinical eﬀectiveness. However, this has been challenged
by a recent study [Minder et al., 2018] showing that performing NFB at school or at the clinic has
no signiﬁcant impact on treatment response.
The type of NFB protocol was not identiﬁed by any method, and did not appear to inﬂuence the
NFB results. This minimal importance granted by the methods to the NFB protocols is counter-
intuitive given the centrality of the protocols in the neurophysiological mode of action and subsequent
expected impact on therapeutic eﬀectiveness [Vernon et al., 2004]. A possible explanation for this
result is that these protocols were equally eﬃcacious for the populations to whom they were oﬀered
and thereby did not constitute a signiﬁcant explanatory factor. This result, however, does not
preclude a combined and personalized strategy (oﬀering personalized protocols based on phenotypes)
to further improve performance, as previously suggested by Alkoby et al. [2017].
Several factors were selected by all three methods with the same direction of inﬂuence: the EEG
quality, the treatment length, and the rater's probably blindness to the treatment. First, our analysis
highlighted that recording EEG in good conditions leads to better results. This can be explained
by the fact that better signal quality enables more accurate extraction of EEG patterns linked to
ADHD and hence leads to better learning and therapeutic eﬃcacy [Congedo et al., 2004]. However,
it remains diﬃcult to assess the quality of EEG hardware (such as the ampliﬁer used) because little
information is provided in these studies. This calls for greater care in future studies, which should
strive to assess and report the quality of the data.
Next, it appears that the longer the course of treatment, the less eﬃcient it becomes. This may
be explained by the degree of engagement with NFB intervention: it may be harder to be engaged
with a long course of treatment. However, it is diﬃcult to quantify because either no questionnaires
assessing engagement were submitted to children or this information was not provided. It is an
interesting point to investigate, so we invite future studies to share it if possible.
Arguably, the treatment length is a proxy for treatment intensity, suggesting that a shorter
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period of treatment is more likely to succeed because the frequency of the sessions is higher. This
hypothesis is supported by the fact that the variable session pace (number of sessions per week) is
also associated with larger within-ES according to the LASSO and the decision tree. The impact
of the intensity of treatment has been investigated by [Rogala et al., 2016] on healthy adults: it
was observed that studies with at least four training sessions completed on consecutive days were
all beneﬁcial. Overall, these results suggest adopting a high session pace, which is not common
knowledge in the ﬁeld.
Some other factors' inﬂuence would have been interesting to investigate, such as using person-
alized NFB protocols based on the iAPF [Liu et al., 2016], which seems promising according to
Bazanova et al. [2018]; Escolano et al. [2014]. However, it could not be included in the SAOB
because only two studies used personalized NFB protocols. This lack of studies is also the reason
why the impact of coupling EMG-Biofeedback with NFB could not be included in the SAOB. An-
other interesting factor, which could have helped explain the result on the treatment duration, was
excluded from the analysis: the severity at baseline. Although pre-test scores were available for each
study, they could not be compared because they were measured on diﬀerent scales. To address this
problem, the scores were normalized using the maximum score to be obtained on each scale. How-
ever, this value was not found for several clinical scales, which led to missing observations. When
more studies including these features will be available, it would be interesting to run the SAOB to
determine the inﬂuence of these excluded factors.
In general our results strongly support the eﬀectiveness of NFB for the treatment of ADHD.
However, as expected, the assessment of symptoms by non-blind raters leads to far more favorable
results than by PBLIND raters, a result widely expected and in close compliance with the existing
meta-analysis [Cortese et al., 2016; Micoulaud-Franchi et al., 2014]. This observation would cer-
tainly be contradictory should teachers' assessments reﬂect a placebo eﬀect, which has long been
documented in the literature [Sollie et al., 2013; Narad et al., 2015; Minder et al., 2018]. This point
is investigated in greater detail in the following section.
4.3 Analysis on the probably blind raters
Teachers were considered as PBLIND raters by Cortese et al. and Micoulaud-Franchi et al.. Unex-
pectedly, the data provided did not exactly match the widely accepted hypothesis stating that the
diﬀerence between MPROX and PBLIND can solely be explained by the placebo eﬀect. Nonethe-
less, the emphasis put on 'probably' indicates that teachers may be aware of the treatment followed.
An element that corroborates this hypothesis is the fact that, for all the studies included in this
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work, the amplitude of the clinical scale at baseline suggests that teachers did not capture the full
extent of the symptoms or, put diﬀerently, that they were blind more to the symptoms than to the
intervention, as illustrated in Figure 4. Indeed, before the intervention, teachers rated the symp-
toms less severely compared to parents and observed less improvement at post-test: this tends to
correspond more to case A with no placebo eﬀect than case B. The expected diﬀerences of ratings
between teachers and parents have been extensively studied [Sollie et al., 2013; Narad et al., 2015;
Minder et al., 2018], observing that teachers are more likely to underrate a child's symptom severity,
especially for younger children. As a consequence, teachers might simply be less likely to observe
a clinical change over the course of the treatment [Sollie et al., 2013; Narad et al., 2015; Minder
et al., 2018]. Moreover, it is also clear that there is more variability in teachers' scores compared to
parents', which could partly explain the lower ES obtained for PBLIND raters, since the variability
deﬂates the ES. In conclusion, using PBLIND as an estimate for correcting the placebo eﬀect does
not appear an appropriate choice.
Another way to highlight a possible placebo eﬀect is to focus on the decision tree illustrated in
Figure 3. The top node splits: on the one hand 46 observations corresponding to MPROX raters
and, on the other, 21 observations corresponding to PBLIND. If the diﬀerences observed between
PBLIND and MPROX raters were due to the placebo eﬀect, one would expect to ﬁnd in the MPROX
sub-tree some factors linked to the perception of the implication in the treatment. This was indeed
the case: treatment length was found to be signiﬁcant but not in the direction corroborating the
hypothesis that they are a part of a placebo eﬀect. Indeed, one would expect that the longer the
treatment, the higher the placebo eﬀect and the greater the within-ES. Instead, the opposite was
found, somewhat invalidating the hypothesis.
Overall, these results suggest that PBLIND assessments could hardly be used to assess placebo
eﬀect as they seem to be blinder to symptoms than to intervention. In the absence of an ethically
[Holtmann et al., 2014] and technically [Birbaumer, 1991] feasible sham for NFB protocols [World
Medical Association, 2000], it is necessary to fall back on an acceptable methodological alternative for
the demonstration of clinical eﬀectiveness. Among those are the analysis of neuromarkers collected
during NFB treatment demonstrating that patients do control the trained neuromarkers; that they
learn (reinforce control over time), and that these possibly lead to lasting brain reorganization (e.g.,
changes in their baseline resting state activity). The speciﬁcity of these changes, in relation to which
neuromarkers were trained and to the clinical improvement, will be an essential component of this
demonstration.
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5 Conclusion
In this work we provide additional elements in favor of the eﬀectiveness of NFB for the treatment of
ADHD. First, we conﬁrm that a subgroup of standard NFB studies shows a statistically signiﬁcant
improvement on PBLIND assessments (k = 4 studies instead of 3, n = 283 patients instead of 158
Cortese et al. [2016]).
Second, we identify technical factors as positive contributors to clinical eﬀectiveness, which
strongly suggests that it is mediated by a real mechanism of action based on EEG conditioning.
Equally, treatment intensity was also found to contribute, corroborating what is known from learning
theory (memory consolidation) [Mowrer, 1960]; that is to say, a more intense treatment leads to an
increased clinical eﬃcacy.
While these ﬁndings certainly contribute to the debate, this work also suggests that the ultimate
demonstration of evidence remains out of reach, as teachers' assessments were partly invalidated as
a proxy for the quantiﬁcation of the placebo eﬀect. As a consequence, using PBLIND endpoints to
address the speciﬁcity of the clinical eﬃcacy is not recommended and we instead advise a reliance
on other available methodological tools. These tools include sham NFB and neuromarker analysis
investigating the speciﬁcity of the EEG changes with respect to trained neuromarkers as well as
changes in clinical endpoints.
This work also oﬀers an open-source toolbox for running meta-analysis and SAOB: the code and
data used are available, thus ensuring the transparency and replicability of these analysis, as well
as fostering future ones. Regarding perspectives, this two-fold methodological framework applied to
NFB for ADHD could be suitable for other NFB applications [Marzbani et al., 2016].
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Figure captions
Figure 1: Flow diagram of selection of studies (last searched on February 12, 2018). The subset (a)
corresponds to the Cortese et al.'s inclusion criteria without the requirement of the presence of a
control group. The subset (b) precisely corresponds to the studies included in Cortese et al. [2016]
and more recent works meeting the same criteria.
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Figure 2: Forest plots showing the between-ES. A negative ES is in favor of NFB. The blue squares
correspond to the ES, the blue diamond to the SE and the green line to the 95% conﬁdence interval.
35
Figure 3: Decision Tree obtained: ES corresponds to the within subject eﬀect size and k to the
number of studies, the importance of variables decreases from the root node. Session length is
measured in minutes, treatment length in weeks, and age in years.
36
Figure 4: Pre-test and post-test scores (± standard error) given by parents (MPROX) in blue and
teachers (PBLIND) in green, dashed line. Data hypothesized under two diﬀerent hypotheses: (A)
no placebo eﬀect, teachers see fewer symptoms altogether so that diﬀerence pre-post is low and
(B) placebo eﬀect, teachers see as many baseline symptoms as parents but do not see as much
improvement. (C) Real data: evolution of parents' and teachers' scores between pre- and post-test
on studies that satisfy Cortese et al.'s inclusion criteria and that provide teachers and parents' scores
on the same scale.
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Table captions
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Table 1: List of all studies included in the three diﬀerent analyses: a) studies originally included in
Cortese et al. [2016] (last searched on August 30, 2015); b) studies satisfying Cortese et al. [2016]'s
criteria (last searched on February 12, 2018); c) studies satisfying Cortese et al. [2016] criteria to
the exception of the part relative to the control group (last searched on February 12, 2018).
Analysis Study Year Size of the NFB group
Arnold et al. 2014 26
Bakhshayesh et al. 2011 18
Beauregard and Levesque 2006 15
Bink et al. 2014 45
Christiansen et al. 2014 14
Gevensleben et al. 2009 59
Heinrich et al. 2004 13
Holtmann et al. 2009 20
Linden et al. 1996 9
Maurizio et al. 2014 13
Steiner et al. 2011 9
Steiner et al. 2014 34
van Dongen-Boomsma et al. 2013 22
a = Replicate
Cortese et al. 13 studies 297
Baumeister et al. 2016 8
Bazanova et al. 2018 17
Strehl et al. 2017 72
b = Update
Cortese et al. 16 studies 394
Bluschke et al. 2016 19
Deilami et al. 2016 12
Drechsler et al. 2007 17
Duric et al. 2012 23
Escolano et al. 2014 20
Fuchs et al. 2003 22
Geladé et al. 2016 39
Kropotov et al. 2005 86
Lee and Jung 2017 18
Leins et al. 2007 19
Li et al. 2013 32
Meisel et al. 2014 12
Mohagheghi et al. 2017 30
Mohammadi et al. 2015 16
Monastra et al. 2002 51
Ogrim and Hestad 2013 13
Strehl et al. 2006 23
c = SAOB 33 studies 846
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Table 2: Comparison between Cortese et al. [2016] results obtained with RevMan [Cochrane Collab-
oration, 2011] and those obtained with the meta-analysis package with our choicesa applied. SEs
and their corresponding p-value (in parenthesis) are presented. With the meta-analysis package, a
negative SE is in favor of NFB unlike Cortese et al..
Working hypothesis
Same as
Cortese et al. [2016] Our choicesa
Parents
Total 0.35 (0.004) −0.32 (0.013)
Inattention 0.36 (0.009) −0.31 (0.036)
Hyperactivity 0.26 (0.004) −0.24 (0.02)
Teachers
Total 0.15 (0.20) −0.11 (0.37)
Inattention 0.06 (0.70) −0.17 (0.16)
Hyperactivity 0.17 (0.13) −0.022 (0.85)
a Post-test values for Arnold et al. are obtained after 40 sessions of NFB and Conners scale is
used for Steiner et al. teachers' outcomes.
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Table 3: Results of the WLS, LASSO and decision tree. For the WLS, a p-value < 0.05 (in bold)
means that the coeﬃcient of the corresponding factor is signiﬁcantly diﬀerent from 0. For the
LASSO, factors not set to 0 (in bold) are selected. For the decision tree, the place of the factor in
the tree is indicated. For the ﬁrst two columns, when the value of the coeﬃcient is negative, the
corresponding factor may lead to better NFB results.
Independent
variables (factors)
Coeﬃcients
found by WLS
(p-value)
Coeﬃcients
found by
LASSO
Place
on the
Decision
Tree
Methodological
PBLIND 0.12 (0.044) 0.12 root node
randomization 0.15 (0.062) 0.044 /
IRB -0.25 (0.01) 0.00 /
Population
age max -0.13 (0.075) 0.00 /
age min 0.025 (0.76) 0.00 /
on drugs -0.091 (0.29) 0.00 /
NFB
implementation
number of sessions -0.36 (0.00) 0.00 2nd node
session length -0.34 (0.001) 0.00 /
treatment length 0.35 (0.00) 0.065 2nd and 3rd
nodes
session pace -0.058 (0.33) -0.0043 4th node
SMR -0.10 (0.13) 0.00 /
beta up central -0.093 (0.44) 0.00 /
theta down 0.043 (0.72) 0.00 /
SCP -0.026 (0.85) 0.00 /
transfer phase 0.44 (0.00) 0.00 /
Quality of
acquisition
more than one ac-
tive electrode
-0.17 (0.010) -0.033 /
EEG quality 2 -0.18 (0.033) -0.032 3rd node
Signal quality
EOG rejection or
correction
-0.35 (0.001) 0.00 /
amplitude-based
artifact rejection
0.052 (0.52) 0.00 /
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